缬沙坦对糖尿病肾病患者血清转化生长因子β1水平的影响被引量：2

Effect of valsartan on Transforming growth factor beta 1 level in serum of patients with diabetic nephropathy

下载PDF

导出

摘要目的探讨缬沙坦对糖尿病肾病患者血清转化生长因子β1(TGF-β1)水平的影响。方法选取我院收治108例糖尿病肾病患者作为研究对象,随机分为55例对照组和53例实验组,用酶联免疫吸附法测定血清TGF-β1水平,并进行组间比较。结果对照组治疗前后的TGF-β1含量虽有所下降,但无统计学意义,P>0.05,而实验组在治疗前后的TGF-β1含量有统计学意义,P<0.05,且在治疗后的对照组和实验组的TGF-β1含量也有统计学差异,P<0.05。结论缬沙坦能抑制TGF-β1的含量,进而能有效的减缓或控制慢性肾损害,使其在糖尿病肾病中减缓肾小球硬化及肾间质纤维化发挥重要作用。 Objective To investigate the effects of valsartan on Transforming growth factor beta 1（TGF-β1）level in serum of patients with diabetic nephropathy.Methods The hospital treated 108 cases of diabetic nephropathy patients as the research object,55 cases were randomly divided into control group and 53 patients in experiment group,Determination of serum TGF-β1levels by ELISA,and compared between the two groups.Results The control group before and after treatment of TGF-β1levels have declined,but the difference was not statistically significant,P〉0.05,The experimental group had statistical significance before and after treatment with TGF-β1levels,P〈0.05,After treatment of the control group and the experimental group of TGF-β1levels have significant difference,P〈0.05.Conclusion Valsartan can inhibit the content of TGF-β1,which can effectively reduce or control of chronic renal damage in diabetic nephropathy,which slows down the glomerular sclerosis and renal interstitial fibrosis play an important role.

作者刘香锟侯超王勇

机构地区冀中能源峰峰集团总医院北院区老年病科

出处《中国实验诊断学》 2015年第6期944-945,共2页 Chinese Journal of Laboratory Diagnosis

关键词转化生子因子β1 缬沙坦糖尿病肾病 Transforming Growth Factor beta1valsartan diabetic nephropathy

分类号 R587.2 [医药卫生—内分泌]

引文网络
相关文献

参考文献6

1白伟伟,赵林双.TGF—β信号通路在糖尿病肾病中的作用[J].临床内科杂志,2013,30(3):212-214. 被引量：4
2Schnaper HW, Jandeska S, Runyan CE, et al. TGF-J31 signaltransduction in chronic kidney disease[J]. Front Biosci,2009.14:2448.
3Bonder WA,Noble NA. Interactions of trnsforming growth fac-tor-(3 and Ang D in renal fibrosis [J]. Hypertension,1998; 31:181.
4Shi-wenX.Stanton LA, Kennedy L, et al. CCN2 is necessary foradhesive responses to trnsforming growth factor-1 in embryonicfibroblasts[J]. J Biol Chem,2006,281:10715.
5MiyajimaA,Chen J,Lawrence C,et al. Antibody to transforminggrowth factor-beta ameliorates tubular apoptosis in unilateral u-reteral obstruction[J], Kidney Int,2000.58:2301.
6华飞,蒋晓红,唐暎,刘震宇,董吉祥,包玉倩.氟伐他汀及缬沙坦对糖尿病肾病相关炎症因子的影响[J].中国综合临床,2011,27(7):709-713. 被引量：10

二级参考文献35

1Vidt DG. Inflammation in renal disease [J]. Am J Cardiol,2006,97 (2A) :20A-27A.
2Inman SR, Stowe NT, Cressman MD, et al. Lovastatin preserves renal function in experimental diabetes [ J]. Am J Med Sci, 1999, 317(4) :215-221.
3陆再英,钟南山.内科学[M].7版.北京:人民卫生出版社,2008:775.
4Schnaper HW, Jandeska S, Runyan CE, et al. TGF-β signal transduction in chronic kidney disease. Front Biosci,2009,14:2448-2465.
5Siegel PM, Massague J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer,2003,3:807-821.
6Lopez-Novoa JM, Rodriguez-Pena AB, Ortiz A, et al. Etiopathology of chronic tubular, glomerular and renovascular nephropathies : clinical im- plications. J Transl Med ,2011,9 : 13.
7Fukami K, Ueda S, Yamagishi S, et al. AGEs activate mesangial TGF- beta- Smad signaling via an angiotensin IT type I recetor interaction. Kidney Int ,2004,66:2137-2147.
8Wolf G. Link between angiotensin II and TGF-beta in the kidney. Miner Electrolyte Metab, 1998,24 : 174-180.
9Shi-wen X, Stanton LA, Kennedy L, et al. CCN2 is necessary for adhe- sive responses to transforming growth factor-beta 1 in embryonic fibro- blasts. J Biol Chem ,2006,281 : 10715-10726.
10Leask A. Targeting the TGF-beta,endothelin-1 and CCN 2 axis to com- bat fibrosis in scleroderma. Cell Signal ,2008,20 : 1409-1414.